ClinicalTrials.gg
CompletedNCT06649006Updated May 13, 2026Results posted

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

A Phase 1 interventional study of Blinatumomab in B-precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Completed at 6 sites in Japan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing blinatumomab in Leukemia — 2 open to participants now, 3 under way, 2 of them phase 3. blinatumomab · Leukemia.

Enrollment
12th of 12
6 · median 69
Started
2025
the only one that year
Phase 1
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
5 of 12
Amgen

Among the 12 studies testing blinatumomab in Leukemia, this one is the 12th largest by enrollment, is the only one that started in 2025, is the only one in phase 1, and was the 12th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

2 of the 12 studies testing blinatumomab in Leukemia are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing blinatumomab in Leukemia, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.

03

Conditions studied

  • B-precursor Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • Leukemia
  • Blincyto®
  • Blinatumomab
  • B-precursor Acute Lymphoblastic Leukemia
  • B-ALL
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese adult participants ≥ 18 years and ≤ 70 years at enrollment.
  • Participant should have newly diagnosed B-cell precursor (BCP)
  • Philadelphia-negative ALL in CR/CRh after induction/consolidation therapy with any MRD (+ or -).
  • CR/CRh as defined in Section 11.10, Appendix 10 after induction and at any time during consolidation chemotherapy with ALL MRD2008/2019/2023 protocol regimen or 3 blocks of Hyper-CVAD.
  • Bone marrow function as defined below:

    • (ANC) (Neutrophils) ≥500/μL
    • ≥50.000/μL (transfusion permitted)
  • Adequate renal and hepatic function:

    • Total (TBL) ≤ 2.0 x (ULN) (ULN; unless Gilbert's Disease or if liver involvement with leukemia)
    • ≥50 mL/min/1.73 m\^2
  • performance status (ECOG PS) ≤ 2.

Exclusion criteria

Exclusion Criteria:

Disease Related

  • Current infiltration of cerebrospinal fluid (CSF) by ALL. If screening CSF demonstrates leukemic blasts, participants must receive intrathecal treatment and demonstrate negative CSF before enrollment and starting blinatumomab infusion.
  • Immunotherapy (eg, rituximab, alemtuzumab) within 4 weeks before start of protocol-specified therapy.

Other Medical Conditions

  • History of relevant central nervous system (CNS) pathology or current relevant CNS pathology (e.g., seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, or coordination or movement disorders).
  • Current disease or history of autoimmune disease with potential CNS involvement.
  • Active uncontrolled infection requiring therapy.
  • History of other within the past 3 years, with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
    • Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Adequately treated breast ductal carcinoma in situ without evidence of disease.
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
    • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.

Prior/Concomitant Therapy

  • Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for intrathecal prophylaxis)
  • Known infection with (HIV) or chronic infection with virus or virus. In Japan, follow the JSH Guidelines for the Management of Hepatitis B Virus Infection version 4 (The Japan Society of Hepatology, 2022) for the screening of Hepatis B virus infection.
  • Radiotherapy within 4 weeks prior to study treatment.

Prior/Concurrent Clinical Study Experience

  • Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). This does not apply to other investigational procedures or participation in observational research studies while participating in this study are excluded.

Other Exclusions

  • Participants of unwilling to use protocol-specified method of during treatment and for an additional 48 hours after the last dose of blinatumomab.
  • Participants who are breastfeeding or who plan to breastfeed while on study through 48 hours after the last dose of blinatumomab.
  • Participants planning to become pregnant or donate eggs while on study through 48 hours after the last dose of blinatumomab.
  • Participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive urine or serum pregnancy test.
  • Participant has known to blinatumomab or to any component of the product formulation.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g., Clinical Outcome Assessments) to the best of the participant and investigator's knowledge.
  • History or evidence of any other disorder, condition, or disease (except for those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety, or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants affected by B-ALL will receive blinatumomab as an intravenous (IV) infusion.

    Drug: Blinatumomab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment. TEAEs are any events that occurred after the participant received trial treatment. A serious TEAE was defined as any untoward medical occurrence that: was immediately life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically important serious event. Treatment-related TEAEs were any AEs that could be considered attributable to the trial treatment.

    Time frame: From first dose until 33 days after last dose of trial; median (min,max) overall duration was 107.4 (41.2, 190.2) days

  2. Number of Participants Experiencing Adverse Events of Interest (EOI)

    An AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment. TEAEs were any events that occurred after the participant received trial treatment.

    Time frame: From first dose until 33 days after last dose of trial; median (min,max) overall duration was 107.4 (41.2, 190.2) days

Secondary outcomes

  1. Steady-state Concentration (Css) of Blinatumomab

    Time frame: Cycle 1: Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29; Cycle 2: Day 1 pre-dose, and Days 2 and 29; Cycles 3 and 4: Day 1 pre-dose, and Day 29

  2. Clearance (CL) of Blinatumomab

    Time frame: Cycle 1: Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29; Cycle 2: Day 1 pre-dose, and Days 2 and 29; Cycles 3 and 4: Day 1 pre-dose, and Day 29

  3. Number of Participants Achieving Minimal Residual Disease (MRD) After Each Cycle of Blinatumomab

    Time frame: Cycles 1-4: Day 29 (each cycle is 42 days)

  4. Number of Participants Achieving Hematologic CR

    Time frame: Cycles 1-4: Day 29 (each cycle is 42 days)

  5. Number of Participants Achieving Hematologic CR With Partial Peripheral Count Recovery (CRh)

    Time frame: Cycles 1-4: Day 29 (each cycle is 42 days)

07

Results

Posted May 13, 2026

Participant flow

Participants were enrolled at 5 trial centers in Japan from 08 January 2025. The primary analysis data is presented based on the data cutoff date of 30 July 2025. The trial is ongoing.

Participant flow — Overall Study
MilestoneEvaluable Participants: BlinatumomabNon-evaluable Participants: Blinatumomab
Started51
Completed blinatumomab during cycle 150
Discontinued blinatumomab treatment during cycle 1 due to ae01
Completed21
Not completed30
Withdrew: Ongoing in the trial30

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment. TEAEs are any events that occurred after the participant received trial treatment. A serious TEAE was defined as any untoward medical occurrence that: was immediately life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was any other medically important serious event. Treatment-related TEAEs were any AEs that could be considered attributable to the trial treatment.

Time frame:
From first dose until 33 days after last dose of trial; median (min,max) overall duration was 107.4 (41.2, 190.2) days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs
ParticipantsEvaluable Participants: BlinatumomabNon-evaluable Participants: Blinatumomab
TEAEs51
Serious TEAEs10
Treatment-related TEAEs31
PrimaryNumber of Participants Experiencing Adverse Events of Interest (EOI)

An AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment. TEAEs were any events that occurred after the participant received trial treatment.

Time frame:
From first dose until 33 days after last dose of trial; median (min,max) overall duration was 107.4 (41.2, 190.2) days
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events of Interest (EOI)
ParticipantsEvaluable Participants: BlinatumomabNon-evaluable Participants: Blinatumomab
Number of Participants Experiencing Adverse Events of Interest (EOI)21
SecondarySteady-state Concentration (Css) of Blinatumomab
Time frame:
Cycle 1: Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29; Cycle 2: Day 1 pre-dose, and Days 2 and 29; Cycles 3 and 4: Day 1 pre-dose, and Day 29

Results for this outcome have not been posted.

SecondaryClearance (CL) of Blinatumomab
Time frame:
Cycle 1: Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29; Cycle 2: Day 1 pre-dose, and Days 2 and 29; Cycles 3 and 4: Day 1 pre-dose, and Day 29

Results for this outcome have not been posted.

SecondaryNumber of Participants Achieving Minimal Residual Disease (MRD) After Each Cycle of Blinatumomab
Time frame:
Cycles 1-4: Day 29 (each cycle is 42 days)

Results for this outcome have not been posted.

SecondaryNumber of Participants Achieving Hematologic CR
Time frame:
Cycles 1-4: Day 29 (each cycle is 42 days)

Results for this outcome have not been posted.

SecondaryNumber of Participants Achieving Hematologic CR With Partial Peripheral Count Recovery (CRh)
Time frame:
Cycles 1-4: Day 29 (each cycle is 42 days)

Results for this outcome have not been posted.

Adverse events

Collected over For AE reporting: from first dose until 33 days after last dose of trial; median (min,max) overall duration was 107.4 (41.2, 190.2) days. For all-cause mortality reporting: from enrolment until end of trial; median [min, max] duration was 44 (16, 94) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evaluable Participants: Blinatumomab0/5 (0%)1/5 (20%)5/5 (100%)
Non-evaluable Participants: Blinatumomab0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventEvaluable Participants: BlinatumomabNon-evaluable Participants: Blinatumomab
Neutrophil count decreasedInvestigations1/50/1
Immune effector cell-associated neurotoxicity syndromeNervous system disorders1/50/1
Most frequent other events
Showing 10 of 14
Most frequent other events
EventEvaluable Participants: BlinatumomabNon-evaluable Participants: Blinatumomab
StomatitisGastrointestinal disorders0/51/1
PyrexiaGeneral disorders0/51/1
Cytokine release syndromeImmune system disorders2/51/1
Immune effector cell-associated neurotoxicity syndromeNervous system disorders1/51/1
Neutrophil count decreasedInvestigations2/50/1
AnaemiaBlood and lymphatic system disorders1/50/1
NeutropeniaBlood and lymphatic system disorders1/50/1
HypogammaglobulinaemiaImmune system disorders1/50/1
Device related infectionInfections and infestations1/50/1
White blood cell count decreasedInvestigations1/50/1

Baseline characteristics

The safety analysis set included all participants that were enrolled and received at least one dose of blinatumomab.

Age, Continuous
Age, Continuous(years)Evaluable Participants: BlinatumomabNon-evaluable Participants: BlinatumomabTotal
Mean42.0 ± 15.754.0 ± NA44.0 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Evaluable Participants: BlinatumomabNon-evaluable Participants: BlinatumomabTotal
Female112
Male404
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Evaluable Participants: BlinatumomabNon-evaluable Participants: BlinatumomabTotal
Hispanic or Latino000
Not Hispanic or Latino516
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Evaluable Participants: BlinatumomabNon-evaluable Participants: BlinatumomabTotal
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Akita University Hospital
    Akita, Akita 010-8543, Japan
  • Kyushu University Hospital
    Fukuoka, Fukuoka 812-8582, Japan
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Kanazawa University Hospital
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Yamagata University Hospital
    Yamagata, Yamagata 990-9585, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jul 2025, 6 months.

Results were first posted in May 2026, 9 months after primary completion.

Of 51 industry-sponsored phase 1 interventional studies under Leukemia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 6 months is below that.

Counting every sponsor, half of 164 studies reached it within 53 months; a quarter within 34 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Jan 8, 2025
Primary completionActual
Jul 30, 2025
CompletionActual
Dec 4, 2025
Results first posted
May 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06649006
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Jan 8, 2025
Primary completion
Jul 30, 2025
Completion
Dec 4, 2025
Results posted
May 13, 2026
Last update
May 13, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion